A significant proportion of patients with seropositive RA receiving NNC0109-0012 , compared to those receiving placebo , achieved treatment responses according to the American College of Rheumatology 20 % ( ACR20 ) ( 59 % versus 21 % ) , ACR50 ( 48 % versus 14 % ) , and ACR70 ( 35 % versus 0 % ) levels of improvement , and showed greater improvements in the Health Assessment Questionnaire disability index ( P = 0.047 ) .